Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Intratumoral Cancer Therapies Global Market Report 2025
Request Sample Buy Now
Global Intratumoral Cancer Therapies Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Intratumoral Cancer Therapies Global Market Report 2025

By Technology (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines ), By Application (Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Other Applications ), By End Users (Hospitals, Cancer Research Centers, Clinics) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Intratumoral Cancer Therapies Market Overview

• Intratumoral Cancer Therapies market size has reached to $140 billion in 2024

• Expected to grow to $243.95 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%

• Growth Driver: Rising Cancer Incidence Fuels Expansion Of Intratumoral Cancer Therapies Market

• Market Trend: Technological Advancements Propel Intratumoral Cancer Therapies Market Growth

• North America was the largest region in 2024.

What Is Covered Under Intratumoral Cancer Therapies Market?

Intratumoral cancer therapies refer to treatments that are directly injected or applied to a tumor. These therapies are specifically designed to target tumor cells and can be used with other cancer treatments, such as chemotherapy and radiation therapy.

The main types of intratumoral cancer therapies are monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, and cytokines. Monoclonal antibodies refer to the particular kind of lab-made protein that can connect to certain bodily targets, including antigens found on the exterior of cancer cells. These are used in various applications such as lung cancer, breast cancer, melanoma, prostate cancer, head and neck cancer, and other applications, and are used by various end users such as hospitals, cancer research centers, and clinics.

Intratumoral Cancer Therapies Global Market Report 2025 Market Size and growth rate 2025 to 2029: Graph

What Is The Intratumoral Cancer Therapies Market Size 2025 And Growth Rate?

The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $140.0 billion in 2024 to $156.96 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to advancements in cancer research, increasing cancer incidence, demand for precision medicine, clinical evidence and research initiatives, unmet medical needs.

What Is The Intratumoral Cancer Therapies Market Growth Forecast?

The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $243.95 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in immunotherapy, increased adoption of precision medicine, clinical trial expansion, rising focus on rare cancers, regulatory support and approvals. Major trends in the forecast period include exploration of intratumoral immunomodulators, integration of image-guided therapies, application of hyperthermia in intratumoral treatments, clinical trials for combination therapies, regulatory support for intratumoral therapies.

The forecast of 11.7% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations may challenge oncology programs by inflating costs of localized immunotherapy agents imported from Switzerland and South Korea, resulting in limited accessible options for solid tumor treatment and higher cancer care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Intratumoral Cancer Therapies Market Segmented?

1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines

2) By Application: Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Other Applications

3) By End Users: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

4) By Cell Therapies: CAR T-Cell Therapy, TCR Therapy

5) By Immune System Modulators: Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists

6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs), Peripheral Blood Lymphocytes (PBLs)

7) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factor (TNF)

What Is Driving The Intratumoral Cancer Therapies Market? Rising Cancer Incidence Fuels Expansion Of Intratumoral Cancer Therapies Market

The increasing incidence of cancer is expected to propel the growth of the intratumoral cancer therapies market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Intratumoral cancer therapies are used in diagnosing and treating cancer that help in avoiding off-target toxicities, dose-limiting toxicities, and adverse effects due to immune stimulation for patients suffering from cancer. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023, reflecting a growth of 3.16% from 1,898,160 in 2021. Therefore, the increasing incidence of cancer is driving the growth of the intratumoral cancer therapies industry.

What Is Driving The Intratumoral Cancer Therapies Market? Immunotherapy Integration Boosts Intratumoral Cancer Therapies Market Growth

The rise in immunotherapy integration is expected to propel the growth of the intratumoral cancer therapies market going forward. Immunotherapy is a type of cancer treatment that uses substances made by the body or in a laboratory to boost the immune system and help the body find and destroy cancer cells. Intratumoral therapies align with the growing focus on immunotherapy, providing a localized and potent means to modulate the immune response within the tumor microenvironment. For instance, in June 2022, The United States Food and Drug Administration (FDA), a US-based federal agency of the Department of health and Human Services approved 35 ICI-based combination immunotherapies in 2022. Therefore, the rise in immunotherapy integration is driving the growth of the intratumoral cancer therapies industry.

Who Are The Major Players In The Global Intratumoral Cancer Therapies Market?

Major companies operating in the intratumoral cancer therapies market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Regeneus Ltd., QBiotics Group, VetDC

What Are The Key Trends Of The Global Intratumoral Cancer Therapies Market? Technological Advancements Propel Intratumoral Cancer Therapies Market Growth

Technological development is a key trend gaining popularity in the intratumoral cancer therapies market. Companies operating in the intratumoral cancer therapies market are adopting new technologies to sustain their position in the market. For instance, in March 2022, Evonik, a US-based, specialty chemical manufacturing company, a novel microparticle technology called EUDRATEC SoluFlow, designed to improve the solubility of active medicinal components in oral medication formulations, in cancer therapies. With the use of this breakthrough technology, chemicals that were previously thought to be insoluble can now be used to create a wider variety of oral medications.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Intratumoral Cancer Therapies Market? Pfizer Collaborates With Cytoreason Ltd For Ai-Driven Drug Discovery In Intestine Cancer Therapeutic

In September 2022, CytoReason Ltd., an Israel-based biotechnology company, collaborated with Pfizer Inc. to use artificial intelligence (AI) for drug discovery and development. Through this agreement, Pfizer's drug research activities will use the company's AI technologies. The arrangement, which may be valued up to $110 million over the following five years, calls for Pfizer to contribute $20 million in stock, provide options to license CytoReason's platform and disease models, and give more project assistance. Prifzer Inc. is a US-based pharmaceutical company that serves intestine cancer therapeutics.

Intratumoral Cancer Therapies Market Merger And Acquisition: Astrazeneca Expands Oncology Portfolio With Acquisition Of Neogene Therapeutics Inc.

In January 2023, AstraZeneca, a UK-based, science-driven biopharmaceutical firm that concentrates on the research, commercialization, and discovery of prescription drugs for oncology and rare diseases, acquired Neogene Therapeutics Inc., for $120 million. This acquisition will open up new avenues for AstraZeneca for the treatment of cancer. Neogene Therapeutics Inc. is a Netherlands-based biotechnology research company that delivers a customized treatment based on TCR genes that target neoantigens detected in the tumor of a specific patient.

Regional Analysis For The Global Intratumoral Cancer Therapies Market

North America was the largest region in the intratumoral cancer therapies market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Intratumoral Cancer Therapies Market?

The intratumoral cancer therapies market consists of revenues earned by entities by chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Intratumoral Cancer Therapies Industry?

The intratumoral cancer therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intratumoral cancer therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Intratumoral Cancer Therapies Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $156.96 billion
Revenue Forecast In 2034 $243.95 billion
Growth Rate CAGR of 11.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines
2) By Application: Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Other Applications
3) By End Users: Hospitals, Cancer Research Centers, Clinics Subsegments: 1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors
4) By Cell Therapies: CAR T-Cell Therapy, TCR Therapy
5) By Immune System Modulators: Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists 6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs), Peripheral Blood Lymphocytes (PBLs) 7) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factor (TNF)
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Regeneus Ltd., QBiotics Group, VetDC
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Intratumoral Cancer Therapies Market Characteristics

3. Intratumoral Cancer Therapies Market Trends And Strategies

4. Intratumoral Cancer Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Intratumoral Cancer Therapies Growth Analysis And Strategic Analysis Framework

5.1. Global Intratumoral Cancer Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Intratumoral Cancer Therapies Market Growth Rate Analysis

5.4. Global Intratumoral Cancer Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Intratumoral Cancer Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Intratumoral Cancer Therapies Total Addressable Market (TAM)

6. Intratumoral Cancer Therapies Market Segmentation

6.1. Global Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monoclonal Antibodies

Vaccines

Checkpoint Inhibitors

Cell Therapies

Immune System Modulator

Adoptive Cell Transfer

Cytokines

6.2. Global Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Lung Cancer

Breast Cancer

Melanoma

Prostate Cancer

Head And Neck Cancer

Other Applications

6.3. Global Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Cancer Research Centers

Clinics

6.4. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Naked Monoclonal Antibodies

Conjugated Monoclonal Antibodies

Bispecific Monoclonal Antibodies

6.5. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Preventive Cancer Vaccines

Therapeutic Cancer Vaccines

6.6. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

PD-1 Or PD-L1 Inhibitors

CTLA-4 Inhibitors

6.7. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cell Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

CAR T-Cell Therapy

TCR Therapy

6.8. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Immune System Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immune Checkpoint Inhibitors

Toll-Like Receptor Agonists

6.9. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Adoptive Cell Transfer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tumor-Infiltrating Lymphocytes (TILs)

Peripheral Blood Lymphocytes (PBLs)

6.10. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cytokines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Interleukins

Interferons

Tumor Necrosis Factor (TNF)

7. Intratumoral Cancer Therapies Market Regional And Country Analysis

7.1. Global Intratumoral Cancer Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Intratumoral Cancer Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intratumoral Cancer Therapies Market

8.1. Asia-Pacific Intratumoral Cancer Therapies Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intratumoral Cancer Therapies Market

9.1. China Intratumoral Cancer Therapies Market Overview

9.2. China Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intratumoral Cancer Therapies Market

10.1. India Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intratumoral Cancer Therapies Market

11.1. Japan Intratumoral Cancer Therapies Market Overview

11.2. Japan Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intratumoral Cancer Therapies Market

12.1. Australia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intratumoral Cancer Therapies Market

13.1. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intratumoral Cancer Therapies Market

14.1. South Korea Intratumoral Cancer Therapies Market Overview

14.2. South Korea Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intratumoral Cancer Therapies Market

15.1. Western Europe Intratumoral Cancer Therapies Market Overview

15.2. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intratumoral Cancer Therapies Market

16.1. UK Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intratumoral Cancer Therapies Market

17.1. Germany Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intratumoral Cancer Therapies Market

18.1. France Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intratumoral Cancer Therapies Market

19.1. Italy Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intratumoral Cancer Therapies Market

20.1. Spain Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intratumoral Cancer Therapies Market

21.1. Eastern Europe Intratumoral Cancer Therapies Market Overview

21.2. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intratumoral Cancer Therapies Market

22.1. Russia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intratumoral Cancer Therapies Market

23.1. North America Intratumoral Cancer Therapies Market Overview

23.2. North America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intratumoral Cancer Therapies Market

24.1. USA Intratumoral Cancer Therapies Market Overview

24.2. USA Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intratumoral Cancer Therapies Market

25.1. Canada Intratumoral Cancer Therapies Market Overview

25.2. Canada Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intratumoral Cancer Therapies Market

26.1. South America Intratumoral Cancer Therapies Market Overview

26.2. South America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intratumoral Cancer Therapies Market

27.1. Brazil Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intratumoral Cancer Therapies Market

28.1. Middle East Intratumoral Cancer Therapies Market Overview

28.2. Middle East Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intratumoral Cancer Therapies Market

29.1. Africa Intratumoral Cancer Therapies Market Overview

29.2. Africa Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intratumoral Cancer Therapies Market Competitive Landscape And Company Profiles

30.1. Intratumoral Cancer Therapies Market Competitive Landscape

30.2. Intratumoral Cancer Therapies Market Company Profiles

30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Intratumoral Cancer Therapies Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. Johnson & Johnson

31.3. Eli Lilly and Company

31.4. F. Hoffmann-la Roche

31.5. Takeda Pharmaceutical Company Ltd.

31.6. GSK plc

31.7. Ziopharm Oncology Inc.

31.8. Celldex Therapeutics Inc.

31.9. Astellas Pharma Inc.

31.10. Sirnaomics

31.11. Checkmate Pharmaceuticals Inc.

31.12. Immunovative Therapies Ltd.

31.13. Idera Pharmaceuticals Inc.

31.14. Daiichi Sankyo

31.15. Philogen S.p.A.

32. Global Intratumoral Cancer Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intratumoral Cancer Therapies Market

34. Recent Developments In The Intratumoral Cancer Therapies Market

35. Intratumoral Cancer Therapies Market High Potential Countries, Segments and Strategies

35.1 Intratumoral Cancer Therapies Market In 2029 - Countries Offering Most New Opportunities

35.2 Intratumoral Cancer Therapies Market In 2029 - Segments Offering Most New Opportunities

35.3 Intratumoral Cancer Therapies Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cell Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Immune System Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Adoptive Cell Transfer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cytokines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Intratumoral Cancer Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Intratumoral Cancer Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Amgen Inc. Financial Performance
  • Table 82: AstraZeneca plc Financial Performance
  • Table 83: Bayer AG Financial Performance
  • Table 84: Bristol-Myers Squibb Company Financial Performance
  • Table 85: Pfizer Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cell Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Immune System Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Adoptive Cell Transfer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cytokines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Intratumoral Cancer Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Intratumoral Cancer Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Amgen Inc. Financial Performance
  • Figure 82: AstraZeneca plc Financial Performance
  • Figure 83: Bayer AG Financial Performance
  • Figure 84: Bristol-Myers Squibb Company Financial Performance
  • Figure 85: Pfizer Inc. Financial Performance

In-Depth Skin Booster Market Report: Business Trends, Growth Factors, and Forecast to 2029

Read More About In-Depth Skin Booster Market Report: Business Trends, Growth Factors, and Forecast to 2029

2025 Analysis: Opportunities and Risks in the Evolving STAY-C For Feed Market

Read More About 2025 Analysis: Opportunities and Risks in the Evolving STAY-C For Feed Market

Global Insights: Sustained Release Excipients Market Expected to Surpass $2.1 Billion by 2029

Read More About Global Insights: Sustained Release Excipients Market Expected to Surpass $2.1 Billion by 2029

2025 Thalassemia Drugs Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Thalassemia Drugs Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

View Report

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

View Report

Interventional Oncology Devices Global Market Report 2025 – By Product (Embolization Devices, Ablation Devices, Support Devices), By procedure (Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial C...

View Report

Veterinary Infectious Disease Diagnostics Global Market Report 2025 – By Infection Type (Viral Infections, Bacterial Infections, Parasitic Infections, Other Infections), By Animal Type (Companion Animal, Food-Producing a...

View Report

Laboratory Refrigerators And Ovens Global Market Report 2025 – By Laboratory Refrigerators (General Purpose Lab Refrigerator, Explosion Proof Refrigerator, Portable Refrigerator, Sub-Zero Refrigerator, Walk-In Refrigerat...

View Report

Neuroendovascular Coil Global Market Report 2025 – By Product Type (Guglielmi Detachable Coils (GDCs), Matrix Coils), By Indication (Ruptured Aneurysm, Unruptured Aneurysm), By Application (Tumor Surgery, Medical Teachin...

View Report

Isobutyraldehyde Global Market Report 2025 – By Type (Food Grade, Pharma Grade, Industrial Grade, Other Types), By Form (Powder, Liquid, Other Forms), By Synthesis Method (Hydroformylation Of Propene, Oxidation Of Isobut...

View Report

Automotive Sheet Metal Components Global Market Report 2025 - By Material (Steel, Aluminum), By Distribution Channel (Offline Sales, Online Sales), By Application (Interior, Drivetrain, Engine, Exterior, Chassis) – Impac...

View Report

Frequently Asked Questions

Intratumoral cancer therapies refer to treatments that are directly injected or applied to a tumor. These therapies are specifically designed to target tumor cells and can be used with other cancer treatments, such as chemotherapy and radiation therapy. For further insights on this market, request a sample here

The market major growth driver - Rising Cancer Incidence Fuels Expansion Of Intratumoral Cancer Therapies Market. For further insights on this market, request a sample here

The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $140 billion in 2024 to $156.96 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to advancements in cancer research, increasing cancer incidence, demand for precision medicine, clinical evidence and research initiatives, unmet medical needs. The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to " $243.95 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in immunotherapy, increased adoption of precision medicine, clinical trial expansion, rising focus on rare cancers, regulatory support and approvals. Major trends in the forecast period include exploration of intratumoral immunomodulators, integration of image-guided therapies, application of hyperthermia in intratumoral treatments, clinical trials for combination therapies, regulatory support for intratumoral therapies. For further insights on this market, request a sample here

The intratumoral cancer therapies market covered in this report is segmented –
1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines
2) By Application: Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Other Applications
3) By End Users: Hospitals, Cancer Research Centers, Clinics Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors
4) By Cell Therapies: CAR T-Cell Therapy, TCR Therapy
5) By Immune System Modulators: Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists
6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs), Peripheral Blood Lymphocytes (PBLs)
7) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factor (TNF) For further insights on this market, request a sample here

North America was the largest region in the intratumoral cancer therapies market in 2024. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the intratumoral cancer therapies market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Regeneus Ltd., QBiotics Group, VetDC . For further insights on this market, request a sample here.

Major trends in this market include Technological Advancements Propel Intratumoral Cancer Therapies Market Growth. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Intratumoral Cancer Therapies Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon